122 results
To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues
Primary:In 1L subjects with metastatic squamous non-small cell lung cancer (NSCLC) receiving investigator*s choice of standard of care chemotherapy (i.e. carboplatin and a taxane):1. Evaluate progression free survival (PFS) per RECIST 1.1 as…
To evaluate the efficacy of cobimetinib plus atezolizumab compared with pembrolizumab, as measured by the primary endpoint of progression-free survival (PFS) by independent review
Primary Objective(s) & Hypothesis(es) In subjects with advanced ROC:1) Objective: To evaluate clinical anti-tumor activity of pembrolizumab monotherapy based on ORR as assessed by CIV per RECIST 1.1 in Cohort A-All Comer group as defined in…
Primary Objective:To evaluate the anti-tumor activity of pembrolizumab (MK-3475) (200 mg Q3W) as 1L therapy in subjects with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Objective…
The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, Pembrolizumab (MK-3475) compared to other chemotherapy drugs of physician*s choice (which includes Capecitabine, Eribulin, Gemcitabine…
The aim of the study is comparison of two and four dental implants supporting an overdenture in the upper jaw for patients who experience problems with retention and stability of the upper denture.
Primary Objectivea) Phase I (Safety Run-in) The primary objective of the Phase I Safety Run-in part is to investigate the safety of IO102 in combination with either pembrolizumab alone or pembrolizumab and chemotherapy (carboplatin and pemetrexed)…
Primary:1) To compare OS in subjects with squamous cell carcinoma of the Esophagus.2) To compare OS in subjects with PD-L1 Combined Positive Score (CPS)*10%3) To compare OS in all subjectsSecondary:1) To evaluate the progression free survival (PFS)…
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, Pembrolizumab (MK-3475) in combination with chemotherapy drugs of physician's choice (which includes Nab-paclitaxel, Paclitaxel or…
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…
Primary ObjectivesParts 2To evaluate the safety and tolerability of INCB001158 for patients with advanced/metastatic and/or treatment-refractory solid tumorsParts 3To evaluate the safety and tolerability of INCB001158 in combination with…
Primary: To evaluate the efficacy of capmatinib plus pembrolizumab in comparison to pembrolizumab alone. Secondary: * To evaluate the anti-tumor activity of capmatinib plus pembrolizumab in comparison to pembrolizumab alone.* To characterize the…
This study is designed to assess the efficacy of pralsetinib as compared to Investigator*s choice platinum-based chemotherapy regimen for patients with metastatic NSCLC harboring an oncogenic RET fusion and who have not received prior systemic…
To demontrate improvement of progression-free survival (PFS) and/or overall survival (OS) with M7824 compared with pembrolizumab in first-line participants with advanced NSCLC with high PD-L1 tumor expression.
To compare disease free and overall survival of RCC patients, after adjuvant treatment with pembrolizumab after surgical renal resection. The objective of the study is to demonstrate that treatment with pembrolizumab, in comparison to placebo, will…
1. To compare pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT with respect to radiographic progression free survival (rPFS)2. To compare pembrolizumab plus enzalutamide plus ADT versus placebp plus enzalutamide…
Primary Objective1. To evaluate the antitumor activity of pembrolizumab in combination with chemotherapy compared with saline placebo in combination with chemotherapy using PFS per RECIST 1.1 as assessed by BICR of imaging.2. To evaluate the…
This translational study focusses on the altered / improved immune response triggered by the addition of radiation to immune checkpoint blockade therapy. The study is investigative in nature.Main study parameters/endpoints:a) Alteration / increase…